Dr. Hugh Levaux, Former CEO of Ninaza, Joins Medidata Solutions as Vice President of Product Strategy
FOR IMMEDIATE RELEASE
Dr. Hugh Levaux, Former CEO of Ninaza, Joins Medidata Solutions
as Vice President of Product Strategy
Pharma Industry Veteran to Manage Medidata’s Product Offerings and
Create New Market Opportunity for Rave®
NEW YORK, NY – April 10, 2007 – Medidata Solutions, a global provider of electronic clinical data capture, management and reporting solutions, today announced the addition of Dr. Hugh Levaux as vice president of product strategy. In this role, Levaux will draw on more than 15 years of experience in pharmaceutical outsourcing, strategic consulting and health outcomes research, as well as expertise in early phase clinical development, late phase registries and safety surveillance programs. Levaux will be responsible for the overall definition and management of Medidata’s product offerings, working to bring together Medidata Rave implementation, hosting and support services to address new and existing market segments and customer requirements.
Levaux joins Medidata from Ninaza, a recent provider of web-based electronic data capture (EDC) solutions. As CEO of Ninaza, he set strategic direction for the company and oversaw daily operations with a specific focus on product development, commercial operations and professional services. Prior to joining Ninaza, Levaux held positions as vice president and general manager of the pharmaceutical/biotechnology practice at CareScience, a supplier of webbased patient database and analysis software. He also previously served as senior vice president at Quintiles Transnational, directing international late phase sales and clinical operations.
“I am very excited to apply my experience in EDC technology, professional services and product development to my new role at Medidata, a company that has been consistently driving the evolution of the e-clinical process,” Levaux said. “Medidata’s innovation and advancements—from both a technology and services perspective—continue to make a significant impact on the way sponsors conduct clinical trials. I look forward to collaborating with a talented team that is committed to customer success to create new market opportunities for Rave.”
Prior to Quintiles, Levaux worked as an analyst for RAND Corporation, where he performed risk assessment on emerging markets and evaluated the adoption of commercial processes and technologies with government and private sector clients. Levaux holds a Ph.D. in policy analysis from the RAND Graduate School and has also received master’s degrees in international economics and international relations from SAIS at Johns Hopkins University and international politics from Université Libre de Bruxelles in Belgium. Additionally, Levaux’s work has been published in leading academic and clinical journals.
“With our launch of Medidata Rave 5.6 earlier this year, Hugh’s ability to implement strategic product initiatives will be invaluable as we continue to meet increasing market demand for Rave and for our expertise in clinical software integration,” said Glen de Vries, chief technology officer of Medidata Solutions. “Hugh’s experience will help us shape how we develop new features in Rave and add critical services that will allow us to approach new customers and enter new markets. We are excited for Hugh to join Medidata, and see his addition to the team as a reflection of the high quality products and services we provide as well as the appeal of our skilled leadership team.”
About Medidata Solutions Worldwide
Medidata Solutions helps the world’s leading pharmaceutical, biotechnology, medical device and research organizations maximize the value of their clinical research investments. Innovative process design, technology and services streamline clinical trials by providing early visibility to reliable clinical data—the lifeblood of every research organization. Working with companies and institutions both large and small, Medidata Solutions helps clinical researchers safely accelerate the process of bringing life-enhancing treatments to market—on six continents and in more than 80 countries. Medidata Solutions brings significant value to its broad client base with deep clinical experience and expertise in more than 20 therapeutic areas, projects in Phase I, II, III, IV, registries and surveillance, and studies with thousands of investigators and tens-of-thousands of subjects. For more information, please visit www.mdsol.com.
Contact:
Susan Lombardo
Lois Paul & Partners
781.782.5767
Susan_Lombardo@lpp.com